Introduction
Imaging of tumor metabolism is important in characterizing the viable active tumor and monitoring response to therapy. As a thymidine analog, the positron emission tomography Electronic supplementary material The online version of this article (https:// doi.org/10.1007/s11307-017-1125-3) contains supplementary material, which is available to authorized users.
Correspondence to: Andreas H. Jacobs; e-mail: ahjacobs@uni-muenster.de (PET) tracer 3′-deoxy-3′- [ 18 F]fluorothymidine ([ 18 F]FLT) is a potential biomarker for imaging of tumor proliferation at baseline and in response to therapy. In analogy to thymidine, [ 18 F]FLT is transported into cells, primarily via the human equilibrative nucleoside transporter 1 (hENT1, [1] ), where it is phosphorylated by thymidine kinase 1 (TK1). As an alternative thymidine-to-DNA pathway, phosphorylated thymidine can be generated by methylation of deoxyuridine monophosphate by thymidylate synthase (TS) (Fig. 1) . Even though numerous studies demonstrate a good correlation of [ 18 F]FLT with cellular proliferation in tumors [2, 3] , several reports show that factors like thymidine kinase 1 [4, 5] or thymidine [6] also affect uptake of this radiotracer. Recently, we demonstrated that [ 18 F]FLT uptake cannot be directly related to proliferation, as determined by immunohistochemistry of Ki67 or 5-bromo-2′-deoxyuridine (BrdUrd) in four non-small cell lung cancer (NSCLC) xenograft models. We showed that high [
18 F]FLT accumulation was detectable in tumors with high thymidine phosphorylase (TP) expression [7] . This was in agreement with a study, demonstrating an association of TP immunohistochemical score and [ 18 F]FLT retention in a clinical setting [8] . In our preclinical study, the presence of TP was accompanied by the corresponding enzymatic activity [7] , which results in degradation of thymidine [9] . [ 18 F]FLT is resistant to the catabolic activity of TP [10, 11] . Hence, in tumors with high TP activity thymidine is degraded. Consequently, lower amounts of thymidine compete with [ 18 F]FLT for cellular uptake and retention, resulting in higher [ 18 F]FLT accumulation, as schematically depicted in Fig. 1 . The relationship between the enzyme and [ 18 F]FLT retention has already been demonstrated by infusion of TP in a preclinical model in vivo [12] and by TP inhibition in vitro [8] , whereas in the latter setting, it was shown that TP inhibition does not alter TK1 or hENT1 activity.
Here, we aimed to identify whether the relationship of TP expression, thymidine levels, and [
18 F]FLT uptake can be detected in a broad range of untreated tumors. Hence, we investigated various tumor models from different institutions with respect to their expression of thymidine metabolism proteins and compared these data with respective [
18 F]FLT uptake and published thymidine concentrations. All animal experiments were carried out by the members of the consortium in accordance with the EU Directive 2010/63/EU and the NCRI Guidelines for the welfare and use of animals in cancer research [13] . The tumor models were chosen in each institute as appropriate for their future evaluation of response to specific therapies. Here, only untreated animals were used to assess [ 18 F]FLT confounding factors at baseline. Study designs differed for the different institutions, and cohorts used for western blot analysis, [ 18 F]FLT PET scans, and thymidine analysis partly overlap, so that in total n = 209 animals were included in this study. All tumors were grown as subcutaneous xenografts or allografts, except for the CC531 liver metastasis model from Radboudumc. Details about the models are listed in Table 1 .
Materials and Methods

Animal Models and Study Design
Western Blot Analysis
Immediately after excision, tumors were frozen in liquid nitrogen, stored at − 80°C, and shipped to WWU on dry ice for analysis of thymidine metabolism proteins. Tumor tissue was homogenized in RIPA buffer (Cell Signaling) by a microdismembrator and 20 μg per sample were subjected to western blot analysis. The PVDF membrane was incubated overnight at Band intensities were quantified by ImageJ (National Institutes of Health), using the Bgel analyzer^function, and normalized to the actin-loading control. To normalize for unequal exposures of different blots, all band intensities were expressed relative to a control sample (an H1975 lysate) that was loaded on all gels.
[ 18 
F]FLT PET Imaging of Small Animals
The scanning procedures of each institution are listed in Table 2 . The animals were not fasted. For quantification, standardized uptake values (SUV max and SUV mean ) were determined.
Statistics
Data are expressed as mean ± standard deviation. Numerical values, as well as number of samples analyzed, are depicted in Suppl. Table 2 . Spearman correlations were calculated (SigmaPlot 13.0), and P values G 0.05 were considered statistically significant.
Results
Tumor lysates from untreated rodents were analyzed for TP and TS expression levels. The representative western blot as well as the quantification revealed large differences between tumors (Fig. 2) . We related the TP and TS expression levels to [ 18 F]FLT uptake in the respective tumors and detected a statistically significant correlation between [ 18 F]FLT SUV max and TP levels (ρ = 0.549, P G 0.05, Fig. 3 ). Also, SUV mean was significantly correlated with TP levels (ρ = 0.582, P G 0.05, Suppl. When relating TP expression to respective previously published tumor thymidine concentrations [14] (confirmation of assay robustness presented in Suppl. Fig. 2 ), we observed a significant correlation (ρ = −0.939, P G 0.001, Fig. 4a ). Moreover, tumor thymidine was inversely correlated with [ 18 F]FLT SUV max (Fig. 4b) and [ 18 F]FLT SUV mean (Suppl. Fig. 3 ). Fig. 3b; Suppl. Fig. 1 ). Moreover, we were able to compare the TP data of ten tumor models with tumor thymidine data published previously [14] . As expected, TP expression negatively correlated with thymidine levels and these thymidine concentrations negatively correlated with [ 18 F]FLT (Fig. 4) . The thymidine data strengthen the TP results presented here, as they provide a link between protein expression and activity. Of note, the data analyzed by Heinzmann et al. [14] only partly overlap with the data presented here, explaining slight differences in the results.
For some tumor models, plasma thymidine levels were available. This parameter would be more easily accessible in the clinical setting. Although these plasma thymidine values weakly correlated with tumor thymidine values in this subset of models, no direct relation of this parameter with TP expression or [
18 F]FLT uptake could be detected (Suppl. Fig. 4) . However, as the sample size for some of the models is low, these data should be treated with caution.
In our setup, immunohistochemistry, [ 18 F]FLT PET measurements and the thymidine assay were only partly performed using the same animals. When looking at overlapping datasets on a per-tumor basis, available from a total of n = 54 tumors, a significant correlation of [
18 F]FLT with TP and thymidine, as well as TP with thymidine can also be detected (Suppl. Fig. 5 ), strengthening the conclusion that these factors are related.
In addition to the single institution studies published so far, covering only a limited spectrum of models [7, 8, 12] , our data provide evidence that the relationship of [ 18 F]FLT, thymidine, and TP can be detected in a wider range of tumors in a multi-center setting. This reinforces the role of TP as a factor affecting [
18 F]FLT uptake. This is of importance for the implementation of this tracer as imaging biomarker for tumor therapy follow-up, potentially improving therapy in clinical cancer research.
Ex vivo analysis of TP expression might potentially help in determining the utility of [ 18 The TS band of the rodent K8484 and CC351 tumors is slightly shifted, which can probably be attributed to speciesspecific differences in the protein sequence. The TP antibody used is not optimized for rodent samples. Hence, these samples were excluded from any correlations. 18 F]FLT uptake can still reflect treatment response, as described in a range of systematic reviews [3, 19] .
In our study, [ 18 F]FLT uptake was determined in different institutions with different scanners and in different rodent models. Therefore, it is even more striking that a statistically significant correlation of [ 18 F]FLT uptake with TP could be observed. These variables also differ in the clinical situation. Hence, we speculate that this relation could also be detected in clinical specimens. Lee et al. have demonstrated an association of [ 18 F]FLT and TP immunohistochemistry score in a cohort of 58 non-small cell lung cancer patients. However, no thymidine analysis was performed [8] . It is known that plasma thymidine levels in humans are much lower than in rodents [6, 20] and that TP levels vary between clinical tumor specimens [21] . Whether this variation is related to thymidine and [
18 F]FLT in the respective tumors remains to be determined.
One limitation of the present study is the fact that protein expression, as determined here, is not necessarily directly related to enzymatic activity. Furthermore, quantification of expression levels via western blot densitometry is only semi-quantitative [22] . Of note, TP western blot results are in line with TP levels determined by immunohistochemistry, as we reported previously [7] . This is of importance, as immunohistochemistry is a more clinically accessible method.
Conclusion
[ 18 F]FLT accumulation in tumors can be influenced by competition with endogenous thymidine, which might be controlled by TP. Hence, our data provide further evidence that TP is a major factor influencing [
18 F]FLT uptake, which should be taken into account when employing this radiotracer in tumor therapy follow-up studies. 
